| scholarly article | Q13442814 |
| P356 | DOI | 10.1093/QJMED/94.1.19 |
| P698 | PubMed publication ID | 11161132 |
| P50 | author | Manuel Ramos-casals | Q42646201 |
| Ricard Cervera i Segura | Q53547424 | ||
| Josep Font | Q73474655 | ||
| Miguel Ingelmo | Q73600642 | ||
| P2093 | author name string | Torras A | |
| Darnell A | |||
| García-Carrasco M | |||
| Sisó A | |||
| P433 | issue | 1 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | circulatory system | Q11068 |
| lupus nephritis | Q1621830 | ||
| P304 | page(s) | 19-26 | |
| P577 | publication date | 2001-01-01 | |
| P1433 | published in | QJM: An International Journal of Medicine | Q7265477 |
| P1476 | title | Cardiovascular risk factors and the long-term outcome of lupus nephritis | |
| P478 | volume | 94 |
| Q36951011 | Advances in lupus and Sjögren's syndrome: a tribute to Josep Font |
| Q36493881 | Alpha-chlorofatty Acid and coronary artery or aorta calcium scores in women with systemic lupus erythematosus. A pilot study. |
| Q21257300 | Association between smoking and chronic kidney disease: a case control study |
| Q39283998 | Cardiovascular Disease Prevention Counseling Program for Systemic Lupus Erythematosus Patients |
| Q37425906 | Cardiovascular disease in systemic lupus erythematosus: the role of traditional and lupus related risk factors |
| Q56907410 | Cardiovascular risk factors in primary Sjögren's syndrome: a case-control study in 624 patients |
| Q87393398 | Chapter 12: Lupus nephritis |
| Q37165278 | Cigarette smoking: an important renal risk factor - far beyond carcinogenesis |
| Q46661747 | Cigarette smoking: an important renal risk factor – far beyond carcinogenesis. |
| Q58801489 | Circulating Angiogenic T Cells Are Increased in Lupus Nephritis Patients |
| Q35947003 | Coagulopathies and the kidney |
| Q34665416 | Comparison of clinical outcomes by different renal replacement therapy in patients with end-stage renal disease secondary to lupus nephritis |
| Q54571803 | Efficacy and safety of multi-target therapy using a combination of tacrolimus, mycophenolate mofetil and a steroid in patients with active lupus nephritis. |
| Q53161789 | Efficacy and safety of tacrolimus for induction therapy in patients with active lupus nephritis. |
| Q37391863 | European consensus statement on the terminology used in the management of lupus glomerulonephritis |
| Q37462538 | Influence of race/ethnicity on response to lupus nephritis treatment: the ALMS study |
| Q37834473 | Lupus nephritis in Colombians: contrasts and comparisons with other populations |
| Q33730536 | Management of cardiovascular complications in systemic lupus erythematosus |
| Q34975939 | Mycophenolate mofetil versus cyclophosphamide for induction treatment of lupus nephritis |
| Q40507229 | NMR based serum metabolomics reveals a distinctive signature in patients with Lupus Nephritis |
| Q43236764 | Oxidative stress and homocysteine metabolism in patients with lupus nephritis. |
| Q41941085 | Previous antimalarial therapy in patients diagnosed with lupus nephritis: influence on outcomes and survival |
| Q37146440 | Randomized, controlled trial of prednisone, cyclophosphamide, and cyclosporine in lupus membranous nephropathy |
| Q57945954 | References |
| Q39069721 | Retrospective review of lupus nephritis in a New Zealand multi-ethnic cohort |
| Q38479339 | Risk factors for renal disease in systemic lupus erythematosus and their clinical implications |
| Q46934492 | Serum protein oxidation and apolipoprotein CIII levels in people with systemic lupus erythematosus with and without nephritis |
| Q80194464 | Survival study by organ disorders in 306 Japanese patients with systemic lupus erythematosus: results from a single center |
| Q38641358 | Sustained remission in lupus nephritis: still a hard road ahead. |
| Q43419630 | Systemic lupus erythematosus and cardiovascular disease |
| Q35168076 | The relationship of cigarette smoking to end-stage renal disease |
| Q58482122 | Thickened carotid intima media thickness and carotid atherosclerosis among lupus nephritis patients: the role of traditional and lupus-specific factors |
| Q42728756 | Treatment of lupus nephritis |
| Q78679215 | [Current therapy of lupus nephritis] |
| Q77114590 | [Lupus nephropathy: implications of a long course] |
| Q74043108 | [Prevalence and clinical significance of hepatitis C virus infection in systemic autoimmune diseases] |
Search more.